Vical Interim Clinical Results Demonstrate Safety and Tolerability
of Inovio Biomedical's Electroporation DNA Delivery Technology
SAN DIEGO--(BUSINESS WIRE)--Jun 7, 2007 - Inovio BiomedicalCorporation (AMEX:INO), focused on the development of DNA vaccinesfor cancers and infectious diseases and a novel alternative tosurgery to treat localized cancers, announced today that thecompany's partner, Vical Incorporated, presented positive interimsafety and tolerability data on 18 subjects from an ongoing Phase Iclinical trial...
Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with
Electroporation DNA Delivery Technology and New Devices at Gene
Therapy Meeting
SAN DIEGO--(BUSINESS WIRE)--Jun 6, 2007 - Inovio BiomedicalCorporation (AMEX:INO), focused on the development of DNA vaccinesfor cancers and infectious diseases and a novel alternative tosurgery to treat localized cancers, announced today the companydelivered multiple presentations on preclinical study results andnew device innovations relating to its el
ectroporation-mediated DNAdelivery te...
Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of
Erbitux for Colorectal and Head and Neck Cancer Patients
CHICAGO, DARMSTADT, Germany, June 5, 2007 – Thisyear’s American Society of Clinical Oncology (ASCO) meetingin Chicago sees a wealth of promising new data presented regardingMerck KGaA’s targeted cancer therapy Erbitux®(cetuximab), further demonstrating the consistent efficacy andversatility of this agent in both first-line and subsequenttreatment of metastatic color...
AEterna Zentaris' Partner, Spectrum, Discloses Detailed Phase 2
Data for Ozarelix, in BPH at Annual AUA Meeting
Ozarelix improved LUTS symptoms and urine flow over 28-week period QUEBEC CITY, May 23, 2007 /PRNewswire-FirstCall/ - AEternaZentaris Inc. , a global biopharmaceutical company focused onendocrine therapy and oncology, today announced that its partnerSp
ectrum Pharmaceuticals presented an abstract outlining detailedPhase 2 results for AEterna Zentaris' fourth-generation luteinizinghormone-r...
Vical's Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA
Vaccine Performance; Yields Antibody Responses Comparable to
Electroporation Without Tolerability Issues
MALAGA, Spain, May 23, 2007 /PRNewswire-FirstCall/ -- VicalIncorporated today announced that in a recently completed animalstudy, a DNA vaccine formulated with the company's patentedVaxfectin(TM) adjuvant and delivered by needle-free injectionyielded significantly higher antibody responses than anunformulated DNA vaccine delivered by needle and syringe. In aseparate animal study, el
ectro...
Spectrum Pharmaceuticals Announces Data From Three Oncology
Programs Presented at the American Association of Cancer Research
Annual Meeting
1 EOquin Instillation Immediately Following Transurethral Resectionis Well Tolerated in Phase 2b Bladder Cancer Study IRVINE, Calif., April 19, 2007 /PRNewswire-FirstCall/ --Sp
ectrum Pharmaceuticals, Inc., today announced results of a Phase2b study of EOquin, in non-invasive bladder cancer and thepresentation of preclinical data of SPI (IRL)-1620 and satraplatinat the annual meeting of th...